Insight

Sam Klempner: DKN-01 with Tislelizumab and Chemotherapy in Advanced Gastric or GEJ Adenocarcinoma

Photo taken from medscape.com

Oct 23, 2024, 14:18

Sam Klempner: DKN-01 with Tislelizumab and Chemotherapy in Advanced Gastric or GEJ Adenocarcinoma

Sam Klempner, Associate Professor at Harvard Medical School, shared on X:

“Adding to the ever growing approaches in GEA

DKN-01 in Combination With Tislelizumab and Chemotherapy as First-Line Therapy in Advanced Gastric or GEJ Adenocarcinoma: DisTinGuish.”

DKN-01 in Combination With Tislelizumab and Chemotherapy as First-Line Therapy in Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: DisTinGuish

Authors: Samuel J. Klempner, Mohamad Bassam Sonbol, Zev A. Wainberg, Hope Elizabeth Uronis, Vi K. Chiu, Aaron James Scott, Syma Iqbal, Mohamedtaki Abdulaziz Tejani, Vincent Chung, Melissa C. Stilian, Mathis Thoma, Ying Zhang, Michael H. Kagey, Jason Baum, Cynthia A. Sirard, Rachel A. Altura, Jaffer A. Ajani.

Sam Klempner

Aaron James Scott cancer Cynthia A. Sirard gastric cancer GEJ adenocarcinoma Hope Elizabeth Uronis Jaffer A Ajani Jason Baum Mathis Thoma Melissa C. Stilian Michael H. Kagey Mohamad Bassam Sonbol Mohamedtaki Abdulaziz Tejani OncoDaily Oncology Rachel A. Altura Sam Klempner Samuel J Klempner Syma Iqbal Tislelizumab Vi K. Chiu Vincent Chung Ying Zhang Zev A. Wainberg

Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Agenus and Tanner Pharma Partner to Expand Global Access to BOT/BAL

Special Coverage